Natco Pharma gains on signing voluntary licensing agreement with Lilly for Baricitinib for Covid-19 in India

Natco Pharma is currently trading at Rs. 925.55, up by 5.00 points or 0.54% from its previous closing of Rs. 920.55 on the BSE.

The scrip opened at Rs. 923.00 and has touched a high and low of Rs. 928.75 and Rs. 923.00 respectively. So far 2212 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 995.05 on 28-Sep-2020 and a 52 week low of Rs. 573.30 on 28-May-2020.

Last one week high and low of the scrip stood at Rs. 945.00 and Rs. 917.10 respectively. The current market cap of the company is Rs. 16785.11 crore.

The promoters holding in the company stood at 48.87%, while Institutions and Non-Institutions held 32.49% and 18.65% respectively.

Natco Pharma has signed a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company, for the manufacture and commercialization of the drug Baricitinib for Covid-19 indication in India. In line with the licensing agreement, Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India. 

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.